BLADDER CANCER · White paper
Bladder Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About bladder cancer — and why its trials are hard
Bladder cancer is predominantly urothelial carcinoma (over 90% of cases), spanning non-muscle-invasive disease (Ta, Tis, T1) treated with transurethral resection and intravesical therapy, and muscle-invasive or metastatic disease requiring systemic treatment. It is the tenth most common malignancy worldwide, with a median diagnosis age near 73 and a three-to-fourfold male predominance driven largely by smoking and occupational carcinogens. The therapeutic landscape has transformed from platinum chemotherapy (cisplatin, gemcitabine, MVAC) and intravesical BCG to immune checkpoint inhibitors, FGFR-targeted therapy, and antibody-drug conjugates. Molecular profiling of FGFR3, TP53, and RB1 now guides patient selection. Trial endpoints range from overall survival and progression-free survival in the metastatic setting to disease-free survival in the adjuvant setting and complete/objective response rates and duration of response for accelerated approvals, with recurrence tracking and quality of life important in non-muscle-invasive disease. Landmark trials such as EV-302, KEYNOTE-045, CheckMate-274, and JAVELIN Bladder 100 have redefined the standard of care.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Pembrolizumab (Keytruda) | 2017 | Platinum-refractory locally advanced/metastatic urothelial carcinoma | KEYNOTE-045 | Overall survival | OS 10.3 vs 7.4 months, HR 0.73, p=0.002 |
| Avelumab (Bavencio) | 2020 | First-line maintenance after platinum chemotherapy | JAVELIN Bladder 100 | Overall survival | OS 21.4 vs 14.3 months, HR 0.69 |
| Enfortumab vedotin + pembrolizumab (Padcev + Keytruda) | 2023 | First-line locally advanced/metastatic urothelial carcinoma | EV-302 / KEYNOTE-A39 | Overall survival and PFS | OS 31.5 vs 16.1 months, HR 0.47; PFS 12.5 vs 6.3 months, HR 0.45 |
| Nivolumab (Opdivo) | 2021 | Adjuvant therapy for high-risk muscle-invasive urothelial carcinoma | CheckMate 274 | Disease-free survival | Median DFS 21 vs 10.9 months, HR 0.70 |
| Erdafitinib (Balversa) | 2019 | Locally advanced/metastatic UC with FGFR2/FGFR3 alterations after platinum | BLC2001 | Objective response rate | ORR approximately 40% in FGFR-altered tumors |
| Nadofaragene firadenovec (Adstiladrin) | 2022 | BCG-unresponsive non-muscle-invasive bladder cancer with CIS | CS-003 phase 3 | Complete response at 3 months | ~51% complete response in CIS cohort (unverified exact value) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in bladder cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Atezolizumab (post-platinum monotherapy) — IMvigor211 | Did not meet primary OS endpoint vs chemotherapy in the overall population | Hierarchical testing in the PD-L1-high subgroup limited the confirmatory OS claim (OS 11.1 vs 10.6 months); indication later narrowed |
| Sacituzumab govitecan — TROPiCS-04 (confirmatory) | Confirmatory trial did not support the accelerated approval; withdrawn from urothelial indication | Failure to confirm benefit and safety signals led the sponsor to withdraw the bladder indication |
Choosing the right endpoint
Primary endpoints that matter in bladder cancer trials
- Overall survival (OS) — Gold-standard efficacy measure; needs long follow-up and can be confounded by crossover
- Progression-free / disease-free survival — PFS in metastatic disease, DFS in the adjuvant setting; sensitive to assessment schedule and blinded review
- Complete response (CR) — Key for BCG-unresponsive NMIBC and for accelerated approvals; requires standardized imaging/cystoscopy
- Objective response rate (ORR) and duration of response — RECIST 1.1-based; supports single-arm accelerated approvals in refractory disease
- Recurrence rate / quality of life — Central to NMIBC given up to 50-70% recurrence and the burden of surveillance
How iNGENū runs bladder cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Bladder Cancer clinical trials — FAQs
What changed first-line treatment for metastatic bladder cancer?
How is BCG-unresponsive non-muscle-invasive bladder cancer treated?
Why does FGFR testing matter in bladder cancer?
Ready to discuss your bladder cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal